Clinical Trial Update: Fragmin in Ovarian Cancer: Utility on Survival (FOCUS) [Phase 2]

View source ↗

Summary

Phase 2 trial FOCUS evaluated dalteparin (Fragmin) for potential survival benefit in ovarian cancer; the study status is completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Ovarian Cancer

Drugs mentioned

• FRAGMIN (DALTEPARIN SODIUM)

Snippet

Sponsor: Ontario Clinical Oncology Group (OCOG) | Conditions: Ovarian Cancer | Phase 2 | Status: COMPLETED